Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06073301 · ClinicalTrials.gov registry record · Phase 4
AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF
A Phase 4 study of Necrotizing Fasciitis, sponsored by Kerecis.
- Active
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06073301: Active Phase 4 study of Necrotizing Fasciitis, sponsored by Kerecis.
NCT06073301 is a Phase 4 study of Necrotizing Fasciitis that is active but no longer recruiting, run by Kerecis. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06073301, a Phase 4 study of Necrotizing Fasciitis, is active but no longer recruiting, sponsored by Kerecis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Necrotizing Fasciitis (NF) is a potentially life-threatening soft tissue infection. This study is comparing acellular fish skin graft (AFS) to standard of care allograft (AHC) in the treatment of NF. The purpose of this study is to compare clinical outcomes and time until autograft take in patients that were treated with AHC or AFS prior to permanent autografting to treat NF.
Primary Outcome
To compare the time (number of days) from the first application of study product to time (number of days ) to autografting.
Conditions Studied
Interventions
- DEVICE Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT)
- OTHER Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT)
Study Locations (1)
Georgia
- Joseph M. Still Research Foundation - Augusta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-01 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 4 |
What the registry record for NCT06073301 still lists
NCT06073301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Necrotizing Fasciitis appearing as the primary indexed condition, and to 2 interventions - of which Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT) is the first listed.
NCT06073301 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT06073301 about?
NCT06073301 is a clinical study titled "AFS Compared to AHC in Treatment of Necrotizing Fasciitis NF". Necrotizing Fasciitis (NF) is a potentially life-threatening soft tissue infection. This study is comparing acellular fish skin graft (AFS) to standard of care allograft (AHC) in the treatment of NF. The purpose of this study is to compare clinical outcomes and time until autograft take in patients ...
What is the current status of trial NCT06073301?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2023-08-01. Estimated completion is 2025-12-01.
What conditions does trial NCT06073301 study?
This clinical trial studies the following conditions: Necrotizing Fasciitis.
What interventions are being tested in trial NCT06073301?
The interventions under investigation include: Acellular Fish Skin Graft (AFS) with Standard of Care Negative Pressure Wound Therapy (NPWT) (DEVICE), Acellular Human Cadaver (AHC) with Standard of care Negative Pressure Wound Therapy (NPWT) (OTHER).
Who is sponsoring clinical trial NCT06073301?
This trial is sponsored by Kerecis, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06073301 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06073301's enrollment target sits among peer trials
30 1552nd of 2000 higher than 368 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI